| Id: | acc1584 |
| Group: | 2sens |
| Protein: | CREB |
| Gene Symbol: | CREB1 |
| Protein Id: | P16220 |
| Protein Name: | CREB1_HUMAN |
| PTM: | phosphorylation |
| Site: | Ser133 |
| Site Sequence: | LNDLSSDAPGVPRIEEEKSEE |
| Disease Category: | Cancer |
| Disease: | Breast Cancer |
| Disease Subtype: | |
| Disease Cellline: | MCF7 |
| Disease Info: | |
| Drug: | Radiotherapy |
| Drug Info: | - |
| Effect: | modulate |
| Effect Info: | The mechanism is to reduce CREB phosphorylation and enhance the efficacy of radiotherapy by inhibiting the activity of CREB (using CRE-decoding oligonucleotides). |
| Note: | |
| Score: | 4.0 |
| Pubmed(PMID): | 26655813 |
| Sentence Index: | 26655813_4-5 |
| Sentence: | "We postulated that CREB inhibition via CRE decoy oligonucleotide increases tumor cell sensitization to gamma-irradiation-induced cytotoxic stress. In the present study, we demonstrate that CREB phosphorylation and CREB DNA-protein complex formation increased in time- and radiation dose-dependent manners, while there was no significant change in total protein level of CREB." |
Sequence & Structure:
MTMESGAENQQSGDAAVTEAENQQMTVQAQPQIATLAQVSMPAAHATSSAPTVTLVQLPNGQTVQVHGVIQAAQPSVIQSPQVQTVQISTIAESEDSQESVDSVTDSQKRREILSRRPSYRKILNDLSSDAPGVPRIEEEKSEEETSAPAITTVTVPTPIYQTSSGQYIAITQGGAIQLANNGTDGVQGLQTLTMTNAAATQPGTTILQYAQTTDGQQILVPSNQVVVQAASGDVQTYQIRTAPTSTIAPGVVMASSPALPTQPAEEAARKREVRLMKNREAARECRRKKKEYVKCLENRVAVLENQNKTLIEELKALKDLYCHKSD
Select PDB:
No data.
Protein Tractability:
source: Open TargetsPTM Intensity:
source: CPTACNo intensity data of this site,
show all other sites!
| CREB1-Ser108 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | -0.707 | ||||
| HGSC | |||||
| ccRCC | |||||
| GBM | |||||
| HNSC | |||||
| LUAD | |||||
| LUSC | |||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | 0.707 | ||||
| CREB1-Ser111 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | -0.935 | ||||
| COAD | 0.719 | ||||
| HGSC | |||||
| ccRCC | -0.651 | ||||
| GBM | |||||
| HNSC | 1.355 | ||||
| LUAD | -0.796 | ||||
| LUSC | -0.759 | ||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | 1.067 | ||||
| CREB1-Ser142 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | 1.677 | ||||
| COAD | -0.547 | ||||
| HGSC | -0.852 | ||||
| ccRCC | -0.202 | ||||
| GBM | |||||
| HNSC | -1.472 | ||||
| LUAD | 0.449 | ||||
| LUSC | 0.862 | ||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | 0.086 | ||||
| CREB1-Ser143 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | 0.707 | ||||
| HGSC | -0.707 | ||||
| ccRCC | |||||
| GBM | |||||
| HNSC | |||||
| LUAD | |||||
| LUSC | |||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | |||||
| CREB1-Ser270 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | 0.707 | ||||
| HGSC | -0.707 | ||||
| ccRCC | |||||
| GBM | |||||
| HNSC | |||||
| LUAD | |||||
| LUSC | |||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | |||||
| CREB1-Ser271 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | 0.671 | ||||
| COAD | 0.307 | ||||
| HGSC | -2.002 | ||||
| ccRCC | |||||
| GBM | |||||
| HNSC | |||||
| LUAD | 0.269 | ||||
| LUSC | |||||
| non_ccRCC | 0.591 | ||||
| PDAC | |||||
| UCEC | 0.164 | ||||
| CREB1-Ser340 | |
|---|---|
| Cancer | Intensity |
| BRCA | |
| COAD | 0.347 |
| HGSC | 0.586 |
| ccRCC | |
| GBM | 1.14 |
| HNSC | |
| LUAD | |
| LUSC | -1.245 |
| non_ccRCC | |
| PDAC | -0.829 |
| UCEC | |
PTM-Disease Association:
source: PTMD| Residue | Position | State | Disease | Class | PMID |
|---|---|---|---|---|---|
| S | 133 | D | Alzheimer's disease | Phosphorylation | 23266915 |
| S | 133 | P | Duodenal cancer | Phosphorylation | 12220644 |
| S | 133 | P | Prostate cancer/carcinoma/adenocarcinoma | Phosphorylation | 22710715 |
| S | 133 | P | Lung adenocarcinoma | Phosphorylation | 37407566 |
| S | 133 | U | Multiple sclerosis | Phosphorylation | 33661276 |
| S | 133 | U | Status epilepticus | Phosphorylation | 33661276 |
| S | 133 | U | Acute myeloid leukemia | Phosphorylation | 35322464 |
| S | 133 | U | Prostate cancer | Phosphorylation | 12900420 ; 12900420 ; 33846571 |
| S | 133 | U | Gastric cancer | Phosphorylation | 37409440 |
| S | 133 | U | Synovial sarcoma | Phosphorylation | 35556229 |
| S | 133 | U | Uveal melanoma | Phosphorylation | 32864007 |
State Note: Based on the distinct PTM states in diseases, PTMD classified all disease-associated PTMs into six classes, including whether the up-regulation (U) or down-regulation (D) of PTM levels, the absence (A) or presence (P) of PTMs, and the creation (C) or disruption (N) of PTM sites are associated with diseases.
PTM-Drug Perturbation Response:
source: DecryptMNo data.
Function score:
source: funscoRNo data.
